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ABSTRACT
Immunogenic cell death (ICD) is a well-established instigator of ‘anti-cancer 
vaccination-effect (AVE)’. ICD has shown considerable preclinical promise, yet 
there remain subset of cancer patients that fail to respond to clinically-applied ICD 
inducers. Non-responsiveness to ICD inducers could be explained by the existence of 
cancer cell-autonomous, anti-AVE resistance mechanisms. However such resistance 
mechanisms remain poorly investigated. In this study, we have characterized for 
the first time, a naturally-occurring preclinical cancer model (AY27) that exhibits 
intrinsic anti-AVE resistance despite treatment with ICD inducers like mitoxantrone 
or hypericin-photodynamic therapy. Further mechanistic analysis revealed that this 
anti-AVE resistance was associated with a defect in exposing the important ‘eat me’ 
danger signal, surface-calreticulin (ecto-CRT/CALR). In an ICD setting, this defective 
ecto-CRT further correlated with severely reduced phagocytic clearance of AY27 cells 
as well as the failure of these cells to activate AVE. Defective ecto-CRT in response 
to ICD induction was a result of low endogenous CRT protein levels (i.e. CRTlow-
phenotype) in AY27 cells. Exogenous reconstitution of ecto-rCRT (recombinant-CRT) 
improved the phagocytic removal of ICD inducer-treated AY27 cells, and importantly, 
significantly increased their AVE-activating ability. Moreover, we found that a subset 
of cancer patients of various cancer-types indeed possessed CALRlow or CRTlow-tumours. 
Remarkably, we found that tumoural CALRhigh-phenotype was predictive of positive 
clinical responses to therapy with ICD inducers (radiotherapy and paclitaxel) in lung 
and ovarian cancer patients, respectively. Furthermore, only in the ICD clinical setting, 
tumoural CALR levels positively correlated with the levels of various phagocytosis-
associated genes relevant for phagosome maturation or processing. Thus, we reveal 
the existence of a cancer cell-autonomous, anti-AVE or anti-ICD resistance mechanism 
that has profound clinical implications for anticancer immunotherapy and cancer 
predictive biomarker analysis.
INTRODUCTION
The field of anticancer immunotherapies 
encompassing “active” cell-based vaccines has 
experienced an unprecedented level of development in 
recent times [1]. For most cell-based anticancer vaccines, 
“whole cancer cells” (induced to undergo cell death) 
represent the central element [2]. Thus not surprisingly, 
a significant effort has also been invested in increasing 
the immunogenicity of dying cancer cells used for vaccine 
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production [3–5]. The field has rapidly moved from simple 
induction of freeze-thawing-based necrosis (which is not 
highly immunogenic) to more sophisticated methodologies 
for increasing the “whole cancer cell” immunogenicity 
[5, 6]. One such emerging methodology is ‘immunogenic 
cell death (ICD)’ [7–9].
ICD exhibits high immunogenicity owing to the 
spatiotemporally-defined emission of damage-associated 
molecular patterns (DAMPs) capable of acting as 
immunogenic danger signals [7–9]. Such DAMPs include 
the surface exposed (ecto-), endoplasmic reticulum 
(ER) chaperone, calreticulin (CRT), secreted ATP and 
post-apoptotic released molecules like high-mobility 
group box-1 (HMGB1) protein [7–10]. Amongst these 
DAMPs, the immunogenic ‘eat me’ signal, ecto-CRT 
tends to exclusively associate with ICD [6, 11–14]. In an 
operational sense, ICD activates ‘anti-cancer vaccination 
effect (AVE), i.e., cancer cells undergoing ICD in vitro 
and administered in vivo are capable of eliciting potent 
tumour-rejecting immunity (demonstrated in number of 
mice models) [7]. Moreover, tumour cells undergoing ICD 
in vivo can also activate an “in situ” AVE that “primes” the 
immune system to specifically eliminate residual cancer 
cells [7, 15].
It is noteworthy that, several ICD inducers have 
been applied for clinical treatment of cancer patients, 
either as experimental therapies (e.g. Hypericin-based 
Photodynamic Therapy/Hyp-PDT) or as standards-of-care 
and palliative-care therapies (e.g. radiotherapy, 
mitoxantrone, paclitaxel) [1, 7, 9]. However, despite 
treatment with ICD inducers, there remains a subset 
of patients showing refractoriness to therapy [16–18]. 
Considering the strong preclinical evidence of ICD-
elicited immunity, it is possible that the above subset 
of patients exhibit poor prognosis at least partially due 
to the failure of anti-tumour immunity. Such resistance 
mechanisms need to be urgently characterized since they 
represent major stumbling blocks for the clinical success 
of ICD.
So far, the major naturally-occurring anti-ICD or 
anti-AVE resistance mechanisms have been described 
on the level of host immune system (e.g. mutations in 
immune-receptors that disrupt immunogenicity-sensing) 
[4, 8, 15]. However, considering the centrality occupied by 
cancer cells in the vaccination set-up, it is absolutely vital 
to uncover cancer cell-autonomous mechanisms that reduce 
immunogenicity – an area seldom investigated. Of note, 
our recent meta-analysis advocated the existence of cancer 
cell-autonomous mechanisms ablating immunogenic 
danger signalling [4, 8]. The impact that such resistance 
mechanisms can have, has been confirmed mostly through 
synthetic gene-knockdown/knockout strategies (e.g. 
RNAi) [6, 12, 14, 15]. However, such synthetic strategies 
either harbour the risk of off-target effects or are not 
representative of intrinsic mechanisms [19]. Thus the 
existence of a naturally-occurring experimental model 
exhibiting intrinsic anti-AVE or anti-ICD resistance 
would be critical. Such a model could lead to a better 
understanding of similar resistance mechanisms in a subset 
of patients showing poor prognosis following treatment 
with ICD inducers.
While broad resistance mechanisms not affected by 
ICD inducer-to-inducer differences may exist yet it has 
been proposed that Hyp-PDT might be comparatively less 
susceptible to various resistance mechanisms compared to 
chemotherapy or radiotherapy [4, 20, 21]. Owing to this 
we envisaged that an experimental model showing in vivo 
resistance to Hyp-PDT treatment has the possibility of 
exhibiting the broadest possible AVE-resistant phenotype. 
To this end, we did a literature survey and found one such 
experimental model that fitted this criteria i.e. AY27 rat 
bladder cancer model [22, 23]. Previous studies showed 
that established AY27 tumours in rats exhibited strong 
initial responses to Hyp-PDT treatment, characterized 
by massive tumour-debulking. However, 1–3 weeks 
after treatment, these tumours relapsed thus indicating 
their refractoriness to Hyp-PDT treatment [22, 23]. This 
observation stands in stark contrast to the well-established 
ability of Hyp-PDT to induce bona fide ICD, AVE 
and robust anti-tumour immunity [6, 12, 13, 24, 25] 
e.g. treatment of established CT26 tumours [9] in mice with 
Hyp-PDT was associated with 100% eradication of these 
tumours and not accompanied by relapse, such that even 
re-challenge of these mice with live CT26 cells prevented 
new tumour growth [9, 25]. As a whole this suggests that 
through as-yet-unknown phenomena, AY27 cancer cells 
display the ability to resist the action of a bona fide ICD 
inducer thereby making it an interesting experimental 
model for studying anticancer vaccination resistance.
To this end, the primary aim of this study was 
to investigate whether AY27 is a naturally-occurring 
experimental model of intrinsic resistance to AVE. 
Furthermore, we wished to uncover the mechanism 
underlying this resistance (i.e. ICD based or not). We also 
aimed to investigate, through retrospective meta-analysis 
of publicly available datasets, whether subset of cancer 
patients may exhibit similar disparity. Finally, we wanted 
to ascertain whether the above characterized mechanisms 
of AVE resistance may serve as a ‘predictive biomarker(s)’ 
of the efficacy of ICD inducers in clinical settings.
RESULTS
Rat bladder cancer AY27 cells exhibit intrinsic 
resistance to ‘anticancer vaccination effect’
Based on the findings showing AY27-tumor’s 
tendency to relapse despite treatment with the 
prototypical ICD-inducing agent, Hyp-PDT [22, 23]; 
we decided to examine whether this failure was due to 
the AY27 cells’ inability to activate AVE. In absence 
of a bona fide ICD-susceptible rat cancer model, for 
comparative purposes, we used the CT26 murine cancer 
cells [6, 13]. CT26 cancer model is a well-established 
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AVE/ICD-susceptible model [14, 25, 26]. We exposed 
both CT26 and AY27 cells to two prototypical inducers 
of AVE i.e. Hyp-PDT and the chemotherapeutic, 
mitoxantrone (MTX) for 24 h. The resulting preparations 
of similarly dead or dying, apoptotic, CT26 (Suppl. Fig. 
S1A–S1B) or AY27 cells (Suppl. Fig. S1A–S1B) were 
injected subcutaneously into left flank of syngeneic 
immune-competent BALB/c mice (Fig. 1A) and Fischer 
344 rats (Fig. 1B), respectively. Post-vaccination, these 
rodents were re-challenged with live CT26 (Fig. 1A) 
or AY27 (Fig. 1B) cells as applicable, in the opposite 
flank(s). Thereafter, protection against tumour growth 
at the re-challenge site was interpreted as a sign of 
antitumor vaccination, as described previously [6, 13]. 
The ICD-susceptible CT26 cells exhibited high efficiency 
in activating AVE such that 70–100% BALB/c mice 
‘vaccinated’ with MTX or Hyp-PDT treated CT26 cells 
exhibited efficient tumour-rejecting responses (Fig. 1C). 
In a stark contrast, none of the rats ‘vaccinated’ with 
MTX or Hyp-PDT treated AY27 cells exhibited tumour-
rejecting responses, such that all of them developed 
tumours at the re-challenge site (Fig. 1C).
Figure 1: Rat bladder carcinoma AY27 cells exhibit resistance to ‘anticancer vaccination effect’ associated with ICD 
inducers. CT26 cells A. or AY27 cells B. were treated in vitro with Hyp-PDT (150 nM Hyp incubated for 16 h followed by irradiation 
with light fluence of 2.70 J/cm2) or mitoxantrone (MTX; 1 μM), followed by recovery at 24 h post-treatment. These treated CT26 and AY27 
cells were then injected subcutaneously into BALB/c mice (PBS, n = 10 mice; Hyp-PDT, n = 18 mice; MTX, n = 6 mice) and Fischer 
344 rats (PBS, n = 6 rats; Hyp-PDT, n = 6 rats; MTX, n = 6 rats), respectively. Eight to ten days post-vaccination, the mice and rats were 
challenged in contra-lateral flank with live CT26 (A) and live AY27 (B) cells, respectively. Mice or rats injected with PBS were utilized as 
placebo-controls. C. This was followed by monitoring of tumour incidence at the challenge site. Statistical analysis was performed using 
the Fischer’s exact test; statistical significance between conditions is indicated by the bars (*p < 0.05, **p < 0.01, ***p < 0.0001).
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Rat bladder cancer AY27 cells exhibit disruption 
in calreticulin surface exposure and inefficient 
phagocytic removal by professional phagocytes
The inability of AY27 cells treated with ICD-
inducers to elicit AVE raised a possibility that perhaps 
these cells have some defect in ICD-associated danger 
signalling. To address this possibility, we decided to 
investigate the most important hallmarks of ICD i.e. 
secretion of ATP, release of HMGB1, ecto-CRT and 
efficient phagocytic removal by professional phagocytes.
Analysis of secreted ATP showed that, following 
treatment with MTX or Hyp-PDT, both CT26 and AY27 
cancer cells exhibited increased ATP secretion (Fig. 2A). 
As reported previously [6, 12], Hyp-PDT treatment 
induced rapid ATP secretion (detectable as soon as, 1 h 
post-treatment) in both cell types. On the other hand, 
MTX-elicited ATP secretion was comparatively late (24 h 
post-treatment) (Fig. 2A). ATP secretion by AY27 cells 
after Hyp-PDT was considerably higher than in CT26 cells 
(Fig. 2A); whereas MTX induced similar levels of ATP 
secretion from both cancer cell lines (Fig. 2A). Following 
treatment with MTX or Hyp-PDT, both cancer cell-types 
exhibited increased release of HMGB1 (Fig. 2B), a DAMP 
associated to cell’s secondary necrosis, following a trend 
that paralleled the accumulation of secondary necrotic cells 
in response to these ICD inducers (Suppl. Fig. S1A–S1B).
Next, we analysed the ability of these ICD inducers 
to elicit ecto-CRT. CT26 cancer cells efficiently and 
rapidly mobilized CRT at their surface after both MTX 
and Hyp-PDT treatments (detectable as soon as, 1 h post-
treatment) (Fig. 2C). In stark contrast, ecto-CRT levels 
were strongly reduced (but not nil) in AY27 cancer cells, 
after treatment with both MTX and Hyp-PDT (Fig. 2C). 
This disparity in AY27 cells was also confirmed by cell 
surface protein biotinylation analysis (data not shown). 
As ecto-CRT serves as a potent ‘eat-me signal’, we 
next analysed the ability of these treated cancer cells to 
undergo phagocytic removal by professional phagocytes. 
MTX or Hyp-PDT treated CT26 cells underwent highly 
efficient phagocytosis by the J774 murine phagocytes [27] 
(Fig. 2D). In stark contrast, MTX or Hyp-PDT treated 
AY27 cells were barely phagocytosed by the RMW rat 
phagocytes [28] (Fig. 2D).
We then wondered whether failure to mobilize 
ecto-CRT by the AY27 cells, was a common feature of 
other anticancer therapies known to induce ICD, such 
as radiotherapy [14, 26] or paclitaxel [29]. Moreover 
we expanded our analysis in CT26 and AY27 cells 
also to a prototype of non-ICD inducers, e.g. topotecan 
(a camptothecin analogue) [14]. To this end, we treated 
CT26 and AY27 cells with the above agents and analysed 
ecto-CRT. Similar to the above trends, while radiotherapy 
and paclitaxel both efficiently induced ecto-CRT in CT26 
cells (Fig. 2E) yet these ICD inducers failed to elicit 
similar amounts of ecto-CRT in AY27 cells (Fig. 2E). 
In line with its non-ICD functionality, topotecan failed 
to induce ecto-CRT in both CT26 and AY27 cells (Fig. 2E). 
In aggregate, these results indicate that, compared to CT26 
cells, AY27 cells exhibit defects in ecto-CRT presentation 
in response to ICD inducers, which correlates with their 
inability to undergo efficient phagocytic removal.
Reconstitution of exogenous calreticulin in AY27 
cells increases their phagocytic removal and their 
ability to elicit ‘anticancer vaccination effect’
A correlation analysis of the above data showed that 
across CT26 and AY27 systems, there was a strong, positive 
linear correlation (p < 0.05) between the levels of ecto-CRT 
and efficient phagocytic removal (Fig. 3A) as well as AVE-
inducing capacity (Fig. 3B). This reaffirmed the activity of 
ecto-CRT as an ‘eat me’ signal and an immunogenicity-
definer. To this end, it was imperative to confirm whether 
the disparity in ecto-CRT levels was behind AY27 cells’ 
inefficient phagocytosis and resistance to AVE.
To address this, we analysed the ability of treated 
AY27 cells (post-incubated or not, with exogenously 
‘reconstituted’ recombinant CRT/rCRT) to undergo 
phagocytic removal by professional phagocytes. In line 
with the above observations (Fig. 2D), phagocytosis 
of MTX or Hyp-PDT treated AY27 cells by the RMW 
rat phagocytes was insignificant (Fig. 3C). However, 
reconstitution of ecto-rCRT, statistically significantly 
increased the phagocytic clearance of treated AY27 cells 
by RMW rat phagocytes (Fig. 3C).
Next, we decided to probe the possible functional link 
between the lack of ecto-CRT and AVE-resistance in AY27 
cells. To this end, we exposed AY27 cells to Hyp-PDT 
and MTX for 24 h; and the resulting mixture of dead and 
dying AY27 cells was incubated or not, with exogenously 
‘reconstituted’ ecto-rCRT followed by their injection into 
Fischer 344 rats. This was followed by re-challenging with 
live AY27 cells in the contra-lateral flank (Fig. 3D). In line 
with the above observations (Fig. 1C), rats ‘vaccinated’ 
with MTX or Hyp-PDT treated AY27 cells again failed 
to reject AY27 tumours at the re-challenge site (Fig. 3E). 
However interestingly, injection with vaccines reconstituted 
with ecto-rCRT, significantly increased the number of rats 
(by approximately 50%) capable of resisting AY27 tumour 
growth at the re-challenge site (Fig. 3E). The latter results 
establish low ecto-CRT as a chief defect behind AY27 cell’s 
inability to activate AVE.
Low endogenous levels of calreticulin 
cause disruption in calreticulin surface 
exposure capacity
Ecto-CRT exposure is mediated by a multi-factorial 
signalling pathway [4, 8, 30]. In case of MTX, secondary 
non-lethal ER stress activation and caspases activity 
are required for ecto-CRT [4, 8, 30]. On the other hand, 
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Figure 2: AY27 cancer cells treated with ICD inducers exhibit disruption in the ability to surface expose CRT and 
undergo inefficient engulfment by phagocytic cells. CT26 cells or AY27 cells were treated or not (i.e. untreated controls/CNTR) 
with Hyp-PDT (150 nM Hyp incubated for 16 h followed by irradiation with light fluence of 2.70 J/cm2) or MTX (1 μM). This was followed 
by – A. analysis of extracellular ATP at indicated time points such that the data is presented as relative light units (RLU) values (n = 3; 
mean ± s.e.m.; *p < 0.05, **p < 0.01, ***p < 0.0001 as indicated by bars; Student’s t-test); B. analysis of extracellularly released HMGB1 
in 24 h post-treatment conditioned media via immunoblotting (a graph indicating the mean densitometry intensity of HMGB1 is presented; 
media-only values have been subtracted; n = 3; mean ± s.d.; *p < 0.05, **p < 0.01, versus respective CNTR; Student’s t-test); C. and 
analysis for surface exposed calreticulin in non-permeabilised cells, performed at indicated time-points, such that the data is presented as 
mean fluorescence intensity (MFI) (n = 3; mean ± s.d.; *p < 0.05, **p < 0.01, ***p < 0.0001 versus respective CNTR, ###p < 0.0001 as 
indicated by bars and N.S = non-significant with respect to CNTR; One-way ANOVA with Dunnett’s test for comparison with respective 
CNTR and Bonferroni’s test for comparison between other conditions). D. In another case, the phagocytic engulfment of JADE+CT26 and 
JADE+AY27 cancer cells (recovered 1 h post-treatment) by NIR780+J774 and NIR780+RMW phagocytic cells, respectively, was measured 
after 4 h of co-incubation. Amount of cancer cells phagocytosed by phagocytes were scored by determining the percentage of double 
positive events in FACS analysis (i.e. NIR780+/JADE+, representing phagocytosed cancer cells; data is expressed as fold change with 
respect to/w.r.t. average of respective CNTR; n = 3; mean ± s.e.m.; *p < 0.05, **p < 0.01, ***p < 0.0001 as indicated by the bars; One-
way ANOVA with Dunnett’s test for comparison with respective CNTR and Bonferroni’s test for comparison between other conditions). 
E. CT26 or AY27 cells were treated or not (i.e. untreated controls/CNTR) with paclitaxel (1 μM), radiotherapy (75 Gy) and topotecan 
(2 μM) followed by analysis for surface exposed calreticulin in non-permeabilised cells, performed at 12 h post-treatment time-point. Data 
is presented as mean fluorescence intensity (MFI) (n = 3; mean ± s.e.m.; *p < 0.05, **p < 0.01, ***p < 0.0001 and N.S = non-significant as 
indicated by bars; One-way ANOVA with Bonferroni’s test).
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Figure 3: Reconstituting exogenous CRT in AY27 cancer cells, treated with ICD inducers, improves their ability to 
undergo phagocytosis in vitro and exhibit ‘anticancer vaccination effect’. A correlation analysis was carried out between the 
amount of surface exposed CRT as evident in Fig. 2C and either in vitro phagocytosis of cancer cells by innate immune cells as evident in 
Fig. 2D A. or in vivo anticancer vaccination effect as evident in Fig. 1C B. (*p < 0.05 or **p < 0.01; correlation coefficient and p values 
are mentioned on the graph; Student’s t-test). C–E. Rat bladder carcinoma AY27 cells were treated or not (i.e. untreated controls/CNTR) 
with Hyp-PDT (150 nM Hyp incubated for 16 h followed by irradiation with light fluence of 2.70 J/cm2) or MTX (1 μM). C. Phagocytic 
engulfment of JADE+AY27 cancer cells (recovered 1 h post-treatment and first incubated, or not, with recombinant CRT (rCRT)) by 
NIR780+RMW phagocytic cells was measured after 4 h of co-incubation. Amount of cancer cells phagocytosed by phagocytes were 
scored by determining the percentage of double positive events in FACS analysis (i.e. NIR780+/JADE+, representing phagocytosed cancer 
cells; data is expressed as fold change with respect to/w.r.t. average of CNTR; n = 3; mean ± s.d.; *p < 0.05, **p < 0.01, ***p < 0.0001 
as indicated by the bars; One-way ANOVA with Newman-Keuls test). In another case (D-E), AY27 cells treated in vitro with Hyp-PDT 
or MTX (as described above), were recovered 24 h post-treatment. These cells were incubated (or not) with rCRT for 30 min, washed 
and injected subcutaneously into Fischer 344 rats (PBS, n = 5 rats and PBS+rCRT, n = 5 rats; Hyp-PDT n = 6 rats and Hyp-PDT+rCRT, 
n = 6 rats; MTX, n = 6 rats and MTX+rCRT, n = 6 rats), respectively. Eight to ten days post-vaccination, the rats were rechallenged in 
contra-lateral flank with live AY27 cells D. Rats injected with PBS or PBS plus rCRT were utilized as placebo-controls (5 rats each). This 
was followed by monitoring of tumour incidence at the rechallenge site E. Statistical analysis was performed using the Gehan-Breslow-
Wilcoxon Test; statistical significance is indicated by the bars (*p < 0.05).
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Hyp-PDT–induced ecto-CRT, requires lethal ER stress 
but is not reliant on caspase activation [4, 6, 8, 31]. Thus, 
it was imperative to characterize whether these broad 
signalling events were intact in AY27 cells.
Analysis of the apoptotic module showed that 
both MTX and Hyp-PDT induced increase in the 
amount of cleaved caspase-3 and downstream cleavage 
of PARP (molecular markers of intrinsic apoptosis) 
with similar efficiency in both cancer cell-types (Suppl. 
Fig. S2A). Analysis of ER stress module showed that 
relative to CT26 cells, ER stress responses (marked by 
eIF2α phosphorylation, Suppl. Fig. S2B; BiP/GRP78 
up-regulation and CHOP activation, Suppl. Fig. S2C) 
were not reduced in AY27 cancer cells but were even 
accentuated to a certain extent (especially in case of eIF2α 
phosphorylation, Suppl. Fig. S2B), thus indicating that 
activation of the apoptotic module and ER stress was 
intact in both cancer cell-types. Moreover, inhibition of 
caspases signalling through the pan-caspase inhibitor, 
zVAD-fmk [32], and attenuation of ER stress through a 
well-characterized chemical chaperone, TUDCA [32], 
improved cell survival after Hyp-PDT treatment, in both 
cancer cell-types (Suppl. Fig. S3). In contrast, only pre-
treatment with zVAD-fmk, but not TUDCA, improved 
cellular survival after MTX treatment for both cancer cell-
types (Suppl. Fig. S3). Overall, these results clearly show 
that the activation and signalling functions of ER stress, 
which is mandatory for ecto-CRT emission, is intact in the 
AY27 cells. Of note, these results are substantiated by our 
recent observations of morphological ER stress signatures 
in Hyp-PDT treated AY27 tumours, in vivo [33].
Interestingly, a recent study reported that cells with 
low endogenous levels of CRT show inability in exposing 
ecto-CRT [34]. Interestingly, immunoblotting analysis 
revealed that AY27 cells indeed exhibit approximately 
50%–60% less endogenous CRT expression compared 
to the ICD-susceptible CT26 cells (Fig. 4A). In line 
with this, correlation analysis across different cell lines 
(AY27/CT26) and treatments (CNTR/MTX/Hyp-PDT), 
showed that a strong, positive linear correlation (r = 0.84) 
existed between the endogenous CRT levels and the ability 
to expose ecto-CRT (Fig. 4B) [34]. Similar correlation 
was not found for endogenous actin levels and ecto-CRT 
(r = −0.52), a ‘negative control’ analysis (Fig. 4C).
To further confirm the validity of the above 
conclusions, we decided to stably knock-down the overall 
CRT levels in CT26 cancer cells (via shRNA), to levels 
approximately similar to AY27 cells. Reducing overall CRT 
levels in CT26 cells by 50%–60% (Fig. 4D) significantly 
compromised the ability of these cells to present ecto-CRT 
after MTX or Hyp-PDT treatment (Fig. 4E). Moreover, in 
line with the above analysis, correlation analysis across 
different CT26 clones (CO-shRNA/CRT-shRNA) and 
treatments (CNTR/MTX/Hyp-PDT), showed that a strong, 
positive linear correlation (r = 0.88) existed between the 
endogenous CRT levels and the ability to expose ecto-CRT 
(Fig. 4F) but not between endogenous actin levels and 
ecto-CRT (r = 0.19) (Fig. 4G). Of note, several previous 
studies have shown that knocking down CRT in CT26 cells 
compromises their ability to activate AVE [14, 30, 35, 36], 
an observation that we also confirmed in our CT26 CRT-
shRNA set-up (data not shown).
Taken together these results show that endogenous 
CRT levels positively correlate with the ability of a cell 
to expose ecto-CRT. Moreover, AY27 cells possess a “low 
endogenous CRT expression” phenotype, which is probably 
a major factor behind their inability to present ecto-CRT.
A subset of patients, belonging to various 
cancer-types, exhibit low tumoural 
expression levels of calreticulin
Based on our above preclinical findings, indicating 
that low endogenous levels of CRT could be a crucial 
cell autonomous factor compromising AVE potential; 
we set out to determine whether, a subset of patients 
of various cancer types could show reduced or low 
tumoural expression levels of CRT/CALR. Firstly, 
we carried out a data-mining exercise of publicly 
available DNA sequencing or microarray datasets in 
the Oncomine database [37]. We compared CALR 
levels between tumour tissue and corresponding normal 
tissue (of the same tissue-type), in order to obtain 
Oncomine profiles/analyses with significant CALR 
over/under-expression ratios for each combination, 
which are shown in respective boxes [38]. Of note, each 
analysis represents a logical grouping of samples based 
on standardized sample facts [38]. Through this analysis 
we found that a subset of patients of various cancer types 
have a tendency to show either CALR gene copy-number 
deletions (8 out of 94 total analyses; especially in kidney 
cancer and lung cancer) or, more importantly, CALR 
mRNA under-expression (44 out of 360 total analyses; 
especially in bladder cancer, colorectal cancer, head and 
neck cancer, leukaemia, liver cancer, lymphoma, ovarian 
cancer and sarcoma) in tumoural tissues relative to 
corresponding normal tissues (Fig. 5A).
Next, we decided to confirm whether this phenotype 
i.e. tumoural CALRlow is also “phenocopied” at the protein 
level (i.e. tumoural CRTlow). A data-mining exercise of 
publicly available mass spectrometry-based proteomics 
datasets carried out in the dbDEPC database [39] found 
that certain cohorts of patients for various cancer-types 
have a tendency to show down-regulation of CRT protein 
expression i.e. tumoural CRTlow (between 0.20–0.60 
fold less expression than corresponding normal tissue in 
case of thyroid cancer, hepatocellular cancer and breast 
cancer) (Fig. 5B). Of note, the coverage of dbDEPC in 
terms of number of cancer-types is much more limited 
than Oncomine owing to user-driven, curated submission 
model. In order to increase this coverage, we decided to 
analyse the publicly available tissue-microarray based 
immunohistochemistry datasets in the Human Protein 
Atlas database [40]. We found that there was indeed 
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Figure 4: AY27 cancer cells exhibit low endogenous levels of CRT which are associated with a proportionally low 
surface exposure of CRT in response to ICD inducers. CT26 cells or AY27 cells were treated or not (i.e. untreated controls/
CNTR) with Hyp-PDT (150 nM Hyp incubated for 16 h followed by irradiation with light fluence of 2.70 J/cm2) or MTX (1 μM). This was 
followed by immunoblotting analysis for CRT, 1 h post-treatment A. The calculations based on band densitometry analysis are mentioned 
as applicable i.e. ratio of endogenous levels of CRT to Actin and the fold-change in this ratio relative to CNTR. Moreover, the bands for 
CRT and Actin in A for all the conditions were quantified for their integrated density followed by correlation analysis between the amount 
of surface exposed calreticulin (as evident in Fig. 2C) and endogenous total CRT levels B. or endogenous total Actin levels C. (*p < 0.05; 
correlation coefficient and p value are mentioned on the graph; Student’s t-test). Next, we stably transfected CT26 cancer cells with control-
shRNA (CO-shRNA) or shRNA targeting CRT (CRT-shRNA) and the respective clones thus obtained were treated (or not) as described 
above. This was followed by immunoblotting analysis for CRT, 1 h post-treatment D. The calculations based on band densitometry analysis 
are mentioned as applicable i.e. fold-change in the ratio of endogenous levels of CRT to Actin, relative to CNTR. Analysis for surface 
exposed calreticulin in non-permeabilized (treated or untreated) CT26 CO-shRNA or CRT-shRNA cells, was performed at 1 h post-treatment 
time-point, such that the data is presented as mean fluorescence intensity (MFI) (n = 3; mean ± s.d.; **p < 0.01, ***p < 0.0001 or N.S = non-
significant as indicated by bars; One-way ANOVA with Dunnett’s test for comparison with respective CNTR and Bonferroni’s test for 
comparison between other conditions). Bands for CRT and Actin in (D) for all the conditions were quantified for their integrated density 
followed by correlation analysis between the amount of surface exposed calreticulin E. and endogenous CRT levels F. or endogenous Actin 
levels G. (*p < 0.05; correlation coefficient and p value are mentioned on the graph; Student’s t-test).
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a tendency for a certain subset of patients, for various 
different cancer-types, to show a tumoural CRTlow 
phenotype (especially, skin cancer, renal cancer, glioma 
and breast cancer) (Fig. 5C).
Taken together, our analysis of publicly available 
DNA sequencing, microarray, proteomics and tissue-
microarray datasets, showed that at least a subset of 
patients of various different cancer-types show low 
tumoural expression of CALR/CRT.
Tumoural CALR levels predict the clinical 
efficacy of immunogenic cell death-inducing 
anticancer therapies in lung or ovarian 
cancer patients
On the basis of above results, we set out to determine 
whether CALR expression could predict the tendency of a 
subset of patients with non-small cell lung cancer (hereafter 
refer to as lung cancer) or ovarian cancer to respond to 
Figure 5: A subset of patients, of various cancer types, show low or reduced overall endogenous levels of CRT/CALR. A. 
Differential CALR gene copy numbers or CALR mRNA levels between tissues derived from various cancer types and corresponding normal 
tissues were analysed using the Oncomine database (p-value threshold was set at less than 0.01; all fold changes were deemed valid). Over-
expression or under-expression in the top 1, 5 and 10% are color-coded according to the legend. B. Ratio of differential CRT protein levels 
between tissues derived from various cancer types and corresponding normal tissues were analysed using the dbDEPC 2.0 proteomics 
database. C. Overall CRT protein levels determined in human tumour tissues via tissue microarray analysis-based immunohistochemistry 
were retrieved using the Human Protein Atlas database. Here, the level or overall intensity of antibody-based staining has been used to 
generate three annotated protein expression patterns i.e. high, medium, and low, and no detection levels (colour coded here, in the legend, 
where the intensity of colour indicates the level of expression/staining).
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ICD-inducers but not non-ICD inducers. Of note, reliable 
publicly available datasets for such analysis were not 
available for Hyp-PDT and MTX treatment however such 
datasets were available for radiotherapy (for lung cancer), 
paclitaxel and topotecan (for ovarian cancer); and hence 
analysis proceeded with respective patients left untreated or 
treated with these latter ICD inducers and non-ICD inducer. 
In a setting of untreated lung cancer patients, the differential 
tumoural CALR expression levels (Suppl. Fig. S4A) were 
not significantly relevant in defining the overall survival 
(OS) of patients. However, untreated patients with CALRlow 
tumours tended to show better OS (HR = 1.41, 95% 
CI 0.87–2.27) albeit this trend was not significant (Fig. 6A). 
On the other hand, lung cancer patients treated with the 
ICD inducer radiotherapy and having CALRhigh tumours 
(Suppl. Fig. S4B), tended to have significantly better OS 
than radiotherapy-treated patients with CALRlow tumours 
(HR = 0.28, 95% CI 0.1–0.81) (Fig. 6B). Moreover, in 
ovarian cancer patients treated with the non-ICD inducer 
topotecan the differential tumoural CALR expression levels 
(Suppl. Fig. S4C, S4E) were not significant in defining 
either the OS (Fig. 6C) or progression-free survival (PFS) 
(Fig. 6E) of these patients. In stark contrast, ovarian 
cancer patients treated with the ICD inducer paclitaxel and 
having CALRhigh tumours (Suppl. Fig. S4D, S4F), exhibited 
significantly better OS (Fig. 6D) as well as significantly 
better PFS (Fig. 6F) than paclitaxel treated patients with 
CALRlow tumours (for OS: HR = 0.54, 95% CI 0.33–0.87; 
for PFS: HR = 0.57, 95% CI 0.39–0.83).
Next we evaluated the predictive value of CALR 
expression when the patients are categorized into different 
cohorts according to the different tumour stages. Since 
there were not enough radiotherapy-treated lung cancer 
patients available to allow for such categorization in an 
objective manner, we confined this analysis to ovarian 
cancer. Interestingly, all the patient cohorts based on 
different stages of ovarian cancer showed similar trend 
i.e. Stage 2/3 (Fig. 7A), Stage 3 (Fig. 7C) and Stage 
3/4 (Fig. 7E) ovarian cancer patients treated with the 
ICD inducer paclitaxel and having CALRhigh tumours, 
exhibited significantly better PFS than paclitaxel-treated 
patients with CALRlow tumours (Fig. 7A, 7C, 7E). Very 
interestingly, this positive association between CALRhigh 
tumours and paclitaxel treatment, became stronger 
and more statistically significant as the ovarian cancer 
stages advanced further (for Stage 2/3: HR = 0.67, 95% 
CI 0.46–1.00, p-value = 0.047; for Stage 3: HR = 0.62, 
95% CI 0.42–0.92, p-value = 0.018; and for Stage 3/4: 
HR = 0.51, 95% CI 0.35–0.75, p-value = 0.00057) 
(Fig. 7A, 7C, 7E). On the other hand, the stage of ovarian 
cancer under consideration did not change the inability of 
tumoural CALR expression levels in predicting the patient 
responses to topotecan (Fig. 7B, 7D, 7F).
Together, the above results suggest that high tumoural 
CALR expression predisposes patients with lung and 
ovarian cancer to improved clinical responses following 
radiotherapy or paclitaxel-based anticancer therapy.
Tumoural CALR levels positively correlate with 
levels of phagocytosis-related genes specifically 
in cancer patients treated with immunogenic cell 
death-inducing anticancer therapy
Taken together, our experimental data suggested 
that low endogenous CRT levels leads to reduced ecto-
CRT, which in turn impairs phagocytic removal and 
AVE inducing potential, in ICD settings. In clinical 
terms, we then wondered whether tumoural CALR 
levels in cancer patients treated with ICD inducers (e.g. 
radiotherapy-treated lung or paclitaxel-treated ovarian, 
cancer patients) or not (untreated lung or topotecan-
treated ovarian, cancer patients) had a direct association 
with levels of phagocytosis-related genes. Phagocytosis-
related genes utilized for this co-expression analysis 
included those involved in phagosome maturation (PLD1 
[41], RAB5A [42], RAB7A [43], VAMP7 [44], WAS [45]) 
and phagosome processing (CRK [46], PLA2G4A [46], 
PLA2G5 [47], STAB2 [46], TNFSF11 [48]) in order to 
get as close as possible to active phagocytosis process 
rather than mere presence of phagocytes in the tumour 
(Fig. 8). Interestingly, this correlation analysis showed 
that mainly in the ICD clinical settings tumoural CALR 
levels positively correlated with the tumoural levels of 
phagocytosis-associated genes (especially PLA2G5, PLD1, 
RAB5A, VAMP7, STAB2) (Fig. 8). On the other hand, in 
non-ICD settings, the tumoural CALR levels either didn’t 
or even negatively correlated with the tumoural levels of 
phagocytosis-associated genes (Fig. 8). Moreover, within 
the ICD clinical setting, this positive correlation between 
CALR and phagocytosis-associated genes was higher 
for radiotherapy-treated lung cancer patients than for 
paclitaxel-treated ovarian cancer patients (Fig. 8).
In conclusion, tumoural CALR levels tend to 
positively correlate with levels of tumoural phagocytosis-
associated genes, only in the ICD clinical settings.
DISCUSSION
In the current study we characterized, for the first 
time, a naturally-occurring cancer cell-model that exhibits 
intrinsic resistance towards anticancer vaccination 
(Fig. 9). We went onto characterize that the reason behind 
this is a defect in ecto-CRT-based immunogenicity, 
which makes these cells resistant to ICD-induced 
AVE (Fig. 9). Primary (if not the only) reason behind 
this disparity in AY27 cells seemed to be the relatively 
reduced endogenous protein levels of CRT (Fig. 9). 
Moreover, these interesting preclinical findings and the 
existence of tumours displaying lower CRT expression 
were also supported by the observation that a subset of 
patients of various cancer-types presented CALRlow or 
CRTlow tumours (Fig. 9). Even more importantly, we 
went onto demonstrate that CALR expression levels 
were pivotally predictive of patient clinical responses 
to ICD-inducing anticancer therapies – an observation 
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Figure 6: Cancer patients exhibiting low tumoural CALR levels show poor clinical prognosis in response to paclitaxel 
and radiotherapy. A, B. Lung cancer patients not treated with any therapy (i.e. untreated, n = 227) (A) or treated with radiotherapy 
only (n = 23) (B) were stratified into high (red lines) or low (black lines) expression-based “risk-groups” by considering the median of the 
overall transcript-expressions of CALR (untreated – low n = 63, high n = 164; radiotherapy – low n = 15, high n = 8). This was followed by 
Kaplan-Meier plotting of the patient’s overall survival (OS) (Y-axis). C–D. Ovarian cancer patients treated with topotecan only (n = 119) 
(C) or treated with paclitaxel only (n = 220) (D) were stratified into high (red lines) or low (black lines) expression-based “risk-groups” by 
considering the median of the overall transcript-expressions of CALR (topotecan – low n = 67, high n = 52; paclitaxel – low n = 69, high 
n = 151). This was followed by Kaplan-Meier plotting of the patient’s OS (Y-axis). E–F. Ovarian cancer patients treated with topotecan only 
(a = 118) (E) or treated with paclitaxel only (n = 229) (F) were stratified into high (red lines) or low (black lines) expression-based “risk-
groups” by considering the median of the overall transcript-expressions of CALR (topotecan – low n = 75, high n = 43; paclitaxel – low 
n = 57, high n = 172). This was followed by Kaplan-Meier plotting of the patient’s progression-free survival (PFS) (Y-axis). In all the above 
graphs, respective log-rank test p-values and hazard ratios (HR; with its 95% confidence interval in parenthesis) are displayed. Statistical 
significance (i.e. p < 0.05 or p < 0.001) is indicated through an asterisk (* or **).
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Figure 7: Paclitaxel treated cancer patients with tumoural CALRlow phenotype, show cancer stage-independent poor 
clinical prognosis. A, B. Stage 2/3 ovarian cancer patients treated with paclitaxel (n = 188) (A) or topotecan (n = 103) (B) were stratified 
into high (red lines) or low (black lines) expression-based “risk-groups” by considering the median of the overall transcript-expressions 
of CALR (paclitaxel – low n = 64, high n = 124; topotecan – low n = 25, high n = 78). This was followed by Kaplan-Meier plotting of the 
patient’s progression-free survival (PFS) (Y-axis). C–D. Stage 3 ovarian cancer patients treated with paclitaxel (n = 177) (C) or topotecan 
(n = 100) (D) were stratified into high (red lines) or low (black lines) expression-based “risk-groups” by considering the median of the 
overall transcript-expressions of CALR (paclitaxel – low n = 62, high n = 115; topotecan – low n = 66, high n = 34). This was followed by 
Kaplan-Meier plotting of the patient’s PFS (Y-axis). E–F. Stage 3/4 ovarian cancer patients treated with paclitaxel (n = 217) (E) or treated 
with topotecan (n = 113) (F) were stratified into high (red lines) or low (black lines) expression-based “risk-groups” by considering the 
median of the overall transcript-expressions of CALR (paclitaxel – low n = 54, high n = 163; topotecan – low n = 73, high n = 40). This 
was followed by Kaplan-Meier plotting of the patient’s PFS (Y-axis). In all the above graphs, respective log-rank test p-values and hazard 
ratios (HR; with its 95% confidence interval in parenthesis) are displayed. Statistical significance (i.e. p < 0.05 or p < 0.0001) is indicated 
through an asterisk (* or ***).
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with possibly vital clinical implications (Fig. 9). In fact 
we also observed that, only in the ICD clinical setting, 
tumoural CALR levels positively correlated with the levels 
of phagocytosis-associated genes relevant for phagosome 
maturation/processing. This is a novel observation, 
which at least partially substantiates the pre-clinically 
well-established role of CRT (i.e. ecto-CRT) in mediating 
cancer cell phagocytosis, in clinical samples. Although, a 
more targeted analysis of phagocytosis in clinical tumour 
tissue samples via immunohistochemistry is required to 
further validate these results comprehensively.
AVE-resistance mechanisms represent major 
stumbling blocks for anticancer immunotherapy [4, 49]. 
Thus, in our opinion, approaches striving to characterize 
intrinsic ICD/AVE ‘resistant phenotypes’ are important for 
future research [1]. For instance, a similar approach taken 
on the host immune system-level, led to the discovery 
that naturally-occurring Tlr4 mutation in C3H/HeJ mice 
Figure 8: Overall tumoural CALR levels positively correlate with expression levels of phagocytosis-related genes 
only in cancer patients treated with ICD-inducing therapies. Generation of gene co-expression profiles was accomplished by 
correlating the expression profiles of phagocytosis-related genes (CRK, PLA2G4A, PLA2G5, PLD1, RAB5A, VAMP7, STAB2, TNFSF11, 
WAS, RAB7A) with CALR expression levels for the respective scenarios indicated in the Fig. and Pearson’s correlation coefficient (r) was 
used for indicating tendency to co-express. Thereafter the correlation profiles were clustered and represented through a heat map. The 
colour code is represented as legend.
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caused failure of ICD/AVE – an observation that paved 
way for eventual characterization of a subset of breast 
cancer patients possessing TLR4 SNP polymorphism 
(+896A/G → Asp299Gly) that associated with poor 
prognosis under treatment with ICD inducers [50, 51]. 
This, taken together with the complex and multifactorial 
nature of anticancer vaccination responses [1, 2], reveals 
that several as-yet-uncharacterized experimental models 
with intrinsic resistance to ICD/AVE might exist [52]. 
Our study advocates the systematic identification of such 
models since these can help explain the failure of certain 
subset of patients in responding to ICD-inducers, as 
demonstrated here.
Remarkably, except for ecto-CRT, AY27 cells 
emitted all the other important DAMPs recently shown 
to be crucial for AVE like secreted ATP and released 
HMGB1 [7, 8] (Fig. 9). This shows the pivotal position 
occupied by ecto-CRT at the interface between the cancer 
cells and the host immune system [7, 8]. Moreover, these 
observations prove that amongst this constellation of ICD-
associated DAMPs, ecto-CRT is probably by far the most 
important DAMP – a point suggested partially by other 
studies from our [6, 12, 24] as well as other laboratories 
[11, 14, 53, 54]. For instance, melphalan-treated B78 
melanoma cells used as “vaccines” were found to exhibit 
reduced AVE responses despite the ability of these cells to 
Figure 9: Overall endogenous CRT levels within cancer/tumoural cells dictate the in vivo anti-cancer vaccination effect 
and clinical efficacy of ICD-inducing anticancer therapies. Cancer cells possessing normal or high CRT levels (e.g. CT26), when 
treated with ICD inducing therapies, undergo efficient phagocytosis by phagocytes and activate potent anti-cancer vaccination effect 
(AVE). On the other hand, cancer cells possessing low CRT levels (e.g. AY27), when treated with ICD inducing therapies, undergo 
inefficient phagocytosis by phagocytes and are incapable of activating AVE. However, exogenous “reconstitution” of ecto-CRT through 
addition of recombinant-CRT (rCRT) increases the efficiency of phagocytic clearance and increases AVE-activating capacity of the latter 
cancer cells. In a similar manner, lung or ovarian cancer patients treated with ICD inducers (like radiotherapy or paclitaxel) and having 
CALRhigh tumours, tend to exhibit good clinical prognosis. On the contrary, lung or ovarian cancer patients treated with ICD inducers and 
having CALRlow tumours, tend to exhibit poor clinical prognosis. ATP – adenosine triphosphate, CALR – calreticulin mRNA/transcript, 
CRT – calreticulin protein, HMGB1 – high mobility group box 1, OS – overall survival, PFS – progression-free survival.
Oncotarget26855www.impactjournals.com/oncotarget
secrete ATP and present ecto-HSP90 –a defect that could 
only be corrected by exogenous addition of rCRT [32]. All 
this advocates the integration of rCRT in future anticancer 
vaccination paradigms.
The defective CRT protein expression-level in AY27 
cells observed in this study, is also corroborated by another 
study showing that in vivo, AY27 tumours display reduced 
ability to modulate CALR expression [55]. Moreover, the 
AY27 cells also exhibited a relatively heightened ER stress 
response, a phenomenon that could be a consequence 
of reduction in endogenous CRT protein levels [56]. 
The mechanism that “created” the CRTlow phenotype in 
AY27 cells is not immediately clear. Notably, a recent 
study documented an immune-surveillance mechanism 
that tends to counter-select for cancer cells with reduced 
capacity to expose ecto-CRT [29]. Moreover, certain post-
translational (e.g. sumoylation) or epigenetic mechanisms 
(e.g. microRNA or long non-coding RNA) have also 
been contextually characterized to increase or decrease 
CRT expression-levels [34, 57, 58]. Whether such 
mechanisms are applicable to AY27 cells is a matter of 
speculation and needs further systematic investigation in 
future. Of note, although addition of ecto-rCRT increased 
the phagocytosis of AY27 cells and their AVE-inducing 
capacity yet these increases were still relatively partial in 
comparison to CT26 cell model. This could be because 
other as-yet-unknown DAMPs or immunostimulators 
might also be disrupted in AY27 cells – a hypothesis that 
needs urgent verification in near future. This hypothesis 
though receives some support from an independent study 
showing that the in vivo markers of immunogenicity (e.g. 
increased infiltration of CD3+ or CD45RA+ lymphocytes) 
are reduced within AY27 tumours compared to the peri-
tumoural normal tissue [55].
In clinical terms, our observation of CALR expression 
levels being predictive of clinical responses to ICD inducers 
like radiotherapy/paclitaxel (Fig. 9) but not to untreated or 
non-ICD inducer treated patients is fascinating – owing to 
the recent contradictory evidences surrounding the validity 
of CALR levels as predictive or prognostic biomarker. It has 
been observed that based on the study under consideration, 
high CALR/CRT expression level could have either positive 
[59, 60] or negative [53, 61] prognostic impact, or, either 
robust [62] or non-discernible [63] predictive effect. We 
shed further light on this subject by showing that tumoural 
CALR expression is in fact a context-dependent predictive 
biomarker of anticancer therapy response in cancer patients. 
Such that, while tumoural CALRhigh is predictive of positive 
therapy responses in patients treated with ICD inducers, 
yet differential CALR expression is not predictive of 
responses in untreated or non-ICD inducer treated patients. 
Importantly, a combination of tumoural CALRhigh phenotype 
and application of ICD inducing therapies is what dictates 
better patient survival. Moreover, we also provide the 
first glimpses that tumoural CALR levels might regulate 
phagocytosis in tumours, only in ICD but not non-ICD 
clinical settings. These findings may have important clinical 
implications that need to be further elaborated. It would 
be also important to examine whether tumoural CALR 
expression levels could be exploited for clinical stratification 
or decision-making strategies regarding the type of 
anticancer therapy to be applied for patient treatment.
MATERIALS AND METHODS
Materials and reagents
Hypericin was prepared/purified/stored as described 
in the past [64]. Tauroursodeoxycholic acid (TUDCA) was 
purchased from Merck-Millipore (Darmstadt, Germany) 
while Z-Val-Ala-Asp(OMe)-fmk (zVAD-fmk) was 
purchased from Bachem (Weil am Rhein, Germany). 
Mitoxantrone (MTX) and Anti-actin antibody was 
purchased from Sigma (St. Louis, MO, USA). Topotecan 
and paclitaxel were kind gifts from Prof. Johan Swinnen/
Niamat Ali Khan (KULeuven, Belgium). Antibodies 
against CHOP/P-eIF2α/Total eIF2α/cleaved caspase 3/
PARP/HSP90/Bip/GRP78 were purchased from Cell 
Signaling Technology (Danvers, MA, USA). Anti-
calreticulin antibody (for immunoblotting) was purchased 
from Stressgen (Victoria, BC, Canada). Antibody against 
HMGB1 was purchased from Abcam (Cambridge, UK). 
Anti-HSP70 antibody was purchased from Santa Cruz 
Antibodies (San Francisco, USA). Secondary antibodies 
conjugated to horseradish peroxidase were purchased 
from Cell Signaling Technology (Danvers, MA, USA)/
Abcam (Cambridge, UK). Also, the following secondary 
antibodies were used: goat anti-mouse-DyLight680/goat 
anti-rabbit-DyLight800 (Thermo Scientific, Belgium).
Cell lines and induction of immunogenic 
cell death
CT26, AY27, J774 and RMW cells were cultured at 
37°C under 5% CO
2
 in DMEM containing 4.5 g/L glucose 
and 0.11 g/L sodium pyruvate and supplemented with 2 mM 
glutamine, 100 units/ml penicillin, 100 μg/L streptomycin 
and 10% fetal bovine serum. For induction of immunogenic 
cell death, the cells were cultured in the presence of 
mitoxantrone, radiotherapy or paclitaxel (concentrations 
and incubation timings are mentioned in respective 
figure legends). For Hyp-PDT the cells were incubated with 
150 nM Hypericin (for 16 h) followed by light irradiation 
(2.70 J/cm2) performed as described previously [65].
Generation of CALR-shRNA stable clones of 
CT26 cells
All the TRC1 shRNA clones were in lentiviral 
pLKO.1-puro vector (Sigma-Aldrich) and were 
obtained from the BCCM/LMBP Plasmid collection, 
Department of Biomedical Molecular Biology, Ghent 
University, Belgium (http://bccm.belspo.be/about/
lmbp.php). An empty pLKO.1-puro control vector 
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was used as a control (CO-shRNA) (BCCM/LMBP 
Plasmid collection). Three shRNAs targeted against 
murine CALR mRNA were used i.e. CALR shRNA-1: 
CCGGGAGTGTAAGAACTACAAACAACTCG 
AGTTGTTTGTAGTTCTTACACTCTTTTT (Clone 
ID NM_007591.2–1823s1c1), CALR shRNA-2: 
CCGGGCTGGGTCGAATCCAAACATACTCGAGTA 
TGTTTGGATTCGACCCAGCTTTTT (Clone ID 
NM_007591.2–176s1c1) and CALR shRNA-3: 
CCGGGCAAATATCTATGCCTATGATCTCGAG 
ATCATAGGCATAGATATTTGCTTTTT (Clone ID 
NM_007591.2–976s1c1). Briefly, to generate lentivirus 
particles, HEK 293T cells were seeded in 25 cm2 flasks at 
1.3 × 106 cells per 4 ml and transfected the following day by 
the calcium phosphate method with 4 μg of pLKO.1-puro 
carrying the respective shRNAs or with empty pLKO.1-
puro. Each transfection also included 1.2 μg of a plasmid 
encoding VSV-G (pMD2-VSV-G, Tronolab) and 2.6 μg 
of a plasmid encoding packaging proteins (pCMVdR8.9, 
Tronolab). For more detailed protocol please refer to 
Garg et al. EMBO J (2012) [6]. Knockdown of CRT was 
confirmed by immunoblotting and for further analysis only 
that clone was selected which showed a 50–60% knock-
down of CRT (i.e. clone expressing shRNA-3).
Anticancer vaccination experiments
All mice or rats were maintained in pathogen-free 
conditions and the experiments were performed according 
to the guidelines of the local Ethics Committee of the KU 
Leuven or the UGent. CT26/AY27 cells were incubated 
with either MTX or exposed to Hyp-PDT. After a 24 h 
recovery, 3 × 106 of these cells were injected subcutaneously 
(s.c.) in 200 μl of PBS into the left flank of 7–8 weeks-old 
female BALB/c mice (in case of CT26 cells) from Janvier 
(Bio Services BV, The Netherlands) or 150–175 g female 
Fischer 344 rats (in case of AY27 cells) from Charles 
River Laboratories (Lyon, France). Control mice/rats 
were injected with 200 μl PBS only. Mice/rats were then 
challenged with 5 × 105 live untreated CT26/AY27 cells 
in the other (right) flank 7-days after immunization. The 
‘communication’ of the tumour antigenic-memory to the 
adaptive immune system was studied by scoring tumours’ 
incidence at the challenge site (i.e. in the right flank). For 
this, the mice/rats were monitored every 5–6 days (post-
challenge) for the presence of tumours and the experiment 
was stopped shortly before the tumours in control mice/rats 
could reach either 10% of the total mice weight or a volume 
of 2 cm3 (about 20–50 days). In some cases as applicable, 
the treated cancer cells were pre-coated with rCRT (Abcam) 
by incubating the cells with 3 μg/106 cells rCRT for 30 min 
and washed thereafter, before injection.
In vitro phagocytosis assay
Cancer cells were treated as described above 
and recovered after 1 h. CT26 cells, AY27 cells, J774 
phagocytes and RMW phagocytes were detached with 
TrypLE™ Express (Life Technologies, Carlsbad, CA, 
USA). J774/RMW phagocytes were labelled with 
CellVue® NIR780 and CT26/AY27 cells with CellVue® 
Jade (eBioscience, Vienna, Austria). Respective cancer 
cells and phagocytes (CT26:J774 and AY27:RMW) 
were then incubated at a 1:5 ratio for 4 h. Cells were 
then harvested using TrypLE™ Express and analysed 
on flow cytometer (Attune, Life Technologies, Carlsbad, 
CA, USA). The percentage of cancer cells that were 
phagocytosed was calculated by dividing the number of 
double-positive cell number by the number of the JADE 
positive cells. In some cases as applicable, the treated 
cancer cells were pre-coated with rCRT by incubating the 
cells with 3 μg/106 cells rCRT (Abcam) for 30 min and 
washed thereafter, before co-incubation with phagocytes.
Immunoblotting
Cell lysate preparation for immunoblotting, protein 
concentration analysis and the respective immunoblotting 
analysis was carried out as described previously [6, 32]. 
The detection of signal was done using the Odyssey 
infrared-imaging system (Li-Cor Biosciences, Lincoln, 
NE, USA) or ChemidocTM MP system (Bio-Rad, Nazareth 
Eke, Belgium), as applicable. Densitometric analyses were 
generated using Image J.
Cell viability and apoptosis/cell death analysis
Cells were seeded at 5000 cells per well of a 96-well 
plate. After treatment, cells were analysed via MTS 
assay (Promega), as per the manufacturer’s instructions. 
Annexin-V-APC and SytoxGreen (SyGr) staining for 
apoptosis/cell death analysis and its FACS-based analysis 
was done as described previously [32].
Measurement of damage-associated molecular 
patterns (DAMPs)
After treatment, cells were collected with TrypLE 
Express (Life Technologies, Belgium), washed with 
PBS and with FACS (Flow Cytometry) buffer (2% FBS, 
1% BSA in PBS), incubated for 1 hr at 4°C with anti-
CRT antibody (Abcam, Cambridge, UK), washed and 
incubated for 1 hr at 4°C with goat anti-rabbit-Alexa 
Fluor®647 (Invitrogen, Belgium). After final washes 
cells were incubated in FACS buffer including 1 μM 
Sytox Green (Life Technologies, S7020) for 15 min and 
analysed on Attune Flow Cytometer (Life Technologies). 
The permeabilised cells were excluded from the analysis, 
and the mean fluorescence intensity (MFIs) for ecto-
CRT was analysed. On the other hand, in another case, 
after treatment, extracellular ATP was measured in the 
conditioned media using an ATP Bioluminescent assay 
kit (Sigma, St. Louis, MO, USA) based on luciferin-
luciferase conversion, as described previously [6, 12, 24]. 
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Bioluminescence was assessed by optical top reading 
via FlexStation 3 microplate reader (Molecular Devices 
Inc., Sunnyvale, CA, USA). Last but not least, for 
analysis of post-death released DAMPs, the ‘conditioned’ 
culture media (5–8 ml), were collected and concentrated 
to 200–500 μl via centrifugation (3500 × g for 25–45 min) 
using Pierce Concentrator 7ml/9K filters (Pierce), 
according to the manufacturer’s instructions. They were 
then analysed by immunoblotting as described below.
Clinical dataset and patient survival analysis
For characterization of differential CALR expression 
in patients, analysis was done for - DNA copy-number 
aberrations/mRNA expressions using the Oncomine 
database (http://www.oncomine.org) [37], proteomics-
based protein expression analysis using the dbDEPC 
2.0 database (http://lifecenter.sgst.cn/dbdepc/index.do) 
[39] and tissue microarray-based immunohistochemical 
protein-expression using the Human Protein Atlas (http://
www.proteinatlas.org) [40].
For predictive biomarker analysis, the respective 
microarray gene expression data and clinical survival 
information from TCGA, EGA or GEO databases were 
analysed through the KMPlotter platform [66] for lung 
and ovarian cancer patients. The respective patients were 
stratified into two risk-groups i.e. patient group showing 
high CALR expression and patient group showing low 
CALR expression by considering the median expression 
over the entire dataset. Biased arrays were excluded. The 
effect of differential gene expression was estimated on the 
overall survival (OS) or progression-free survival (PFS) 
of the patients (as applicable) by plotting Kaplan-Meier 
curves. Hazard ratio (and its 95% confidence intervals) 
and logrank P values were calculated (P values less than 
0.05 were considered to be statistically significant). Of 
note, the respective results were selected only if two out of 
three CALR microarray probes supported the same patient 
survival patterns and representative probes or patterns out 
of the final two, were selected on the basis of statistical 
significance (logrank p < 0.05). Patients surviving over the 
follow-up threshold were censored.
Analysis of correlation between CALR levels and 
phagocytosis-related genes’ levels
For generating gene co-expression profiles for 
CALR vs. phagocytosis-related genes in respective 
tumoural samples, the expression profiles of individual 
phagocytosis-related genes were correlated with CALR 
as applicable and Pearson’s correlation coefficient (r) was 
used for indicating tendency to co-express. Thereafter, the 
respective correlation coefficient values were “pooled” 
and hierarchical clustering of these respective correlation-
based gene co-expression profiles was implemented as 
described elsewhere [67] through Cluster 3.0 [68] and 
visualized as a heatmap through TreeView [69] with 
Correlation (uncentered) as the similarity metric and a 
centroid linkage clustering criteria.
Statistical analysis
All statistical analyses were performed using either 
Prism software (GraphPad Software, USA) or GraphPad 
QuickCalcs online software (http://www.graphpad.com/
quickcalcs/index.cfm). Student’s t-test, Fischer’s test 
and One-way ANOVA were used for statistical analysis, 
as applicable and unless otherwise mentioned, with 
significance level set at p < 0.05.
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